Alumis Inc.

NasdaqGS:ALMS Stock Report

Market Cap: US$2.7b

Alumis Management

Management criteria checks 4/4

Alumis' CEO is Matt Babler, appointed in Sep 2021, has a tenure of 4.67 years. total yearly compensation is $5.95M, comprised of 11.4% salary and 88.6% bonuses, including company stock and options. directly owns 0.087% of the company’s shares, worth $2.38M. The average tenure of the management team and the board of directors is 4.2 years and 4 years respectively.

Key information

Matt Babler

Chief executive officer

US$5.9m

Total compensation

CEO salary percentage11.45%
CEO tenure4.7yrs
CEO ownership0.09%
Management average tenure4.2yrs
Board average tenure4yrs

Recent management updates

Recent updates

Seeking Alpha • Mar 25

Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets

Summary Alumis Inc. is upgraded to Buy, reversing a prior Sell, based on strong Phase 3 envudeucitinib psoriasis data and pipeline potential. Envudeucitinib demonstrated efficacy comparable to JNJ's newly approved Icotyde, with 74% PASI 75 and 59% sPGA 0/1 at week 16. ALMS targets NDA submission for envudeucitinib in 2H 2026, with additional data in psoriatic arthritis and SLE expected in 2026. With a $2.91bn market cap and analyst targets of $45–$50, ALMS appears up to 40% undervalued, supported by blockbuster potential and robust cash runway. Read the full article on Seeking Alpha
Analysis Article • Aug 16

Alumis Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

It's been a pretty great week for Alumis Inc. ( NASDAQ:ALMS ) shareholders, with its shares surging 10% to US$4.75 in...
Analysis Article • May 29

News Flash: Analysts Just Made A Substantial Upgrade To Their Alumis Inc. (NASDAQ:ALMS) Forecasts

Alumis Inc. ( NASDAQ:ALMS ) shareholders will have a reason to smile today, with the analysts making substantial...
Seeking Alpha • Nov 28

Alumis: A Best-In-Class TYK2 Inhibitor

Summary Alumis' lead drug, ESK-001, is a potential best-in-class TYK2 inhibitor for treating plaque psoriasis and immunological diseases in general., with phase 3 trial data expected in 1H2026. With around $360M in cash, the company is expecting topline phase 3 data on ESK-001 in 1H2026. Given the risks for future dilution and the need for more safety data on the lead, we see Alumis as a compelling stock to monitor. Read the full article on Seeking Alpha
Seeking Alpha • Oct 04

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Summary With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be the next immunology stock to soar on the Nasdaq? Investors who buy now can get it around 30% under the June 28th IPO price. Alumis is backed by prominent healthcare hedge funds such as Baker Brothers, VenBio, and Cormorant Asset Management. But do the potential gains justify the risk? We take an in-depth look at the company’s pipeline and trial results and deliver our verdict. Read the full article on Seeking Alpha
Seeking Alpha • Sep 16

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Summary Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high selectivity and minimal off-target effects, potentially positioning it as a better alternative to the approved TYK2 inhibitor, Sotyktu. Despite strong midstage trial data and a solid cash runway, the highly competitive market and recent IPO status present significant investment risks. I remain cautious on ALMS, acknowledging its potential but wary of market differentiation and liquidity issues. A wait-and-watch approach is prudent. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Matt Babler's remuneration changed compared to Alumis's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$237m

Dec 31 2025US$6mUS$681k

-US$243m

Sep 30 2025n/an/a

-US$245m

Jun 30 2025n/an/a

-US$228m

Mar 31 2025n/an/a

-US$343m

Dec 31 2024US$11mUS$606k

-US$294m

Sep 30 2024n/an/a

-US$239m

Jun 30 2024n/an/a

-US$189m

Mar 31 2024n/an/a

-US$169m

Dec 31 2023US$5mUS$516k

-US$155m

Compensation vs Market: Matt's total compensation ($USD5.95M) is about average for companies of similar size in the US market ($USD7.10M).

Compensation vs Earnings: Matt's compensation has been consistent with company performance over the past year.

CEO

Matt Babler (60 yo)

4.7yrs
Tenure
US$5,948,289
Compensation

Mr. Martin Babler, also known as Matt, Ph D., serves as an Independent Director at 89bio, Inc. since April 13, 2024. He is Independent Member of Sardona Therapeutics, Inc. from May 2025.Mr. Babler was Cha...

Leadership Team

NamePositionTenureCompensationOwnership
Martin Babler
President4.7yrsUS$5.95m0.087%
$ 2.4m
David Goldstein
Chief Scientific Officer4.7yrsUS$2.01m0.17%
$ 4.8m
Jorn Drappa
Chief Medical Officer & Head of Research and Development3.8yrsUS$1.98m0.0032%
$ 87.0k
John Schroer
Chief Financial Officer4yrsno datano data
Sanam Pangali
Chief Legal Officer & Corporate Secretaryless than a yearno data0.00087%
$ 23.9k
Roy Hardiman
Chief Business & Strategy Officer1.5yrsUS$3.22m0.14%
$ 4.0m
Claire Langrish
Senior VP & Head of Immunology and Translational Science4.7yrsno datano data
Philip Nunn
Senior VP of Pharmacology & Project Team Leader4.7yrsno datano data
Mark Bradley
Chief Development Officer5yrsno data0.049%
$ 1.3m
Kolbot By
Senior VP & Head of Technical Operations4.3yrsno datano data
Grace Halteh
Senior VP & Head of Quality and Regulatory3.7yrsno datano data
Jack Danilkowicz
Chief Commercial Officer1.3yrsno datano data
4.2yrs
Average Tenure
60yo
Average Age

Experienced Management: ALMS's management team is considered experienced (4.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Martin Babler
President4.7yrsUS$5.95m0.087%
$ 2.4m
James Tananbaum
Independent Director5yrsno datano data
Srinivas Akkaraju
Independent Director2.2yrsUS$213.96kno data
Sapna Srivastava
Lead Independent Director3.8yrsUS$225.73k0%
$ 0
Lynn Tetrault
Independent Director1yrUS$190.14k0%
$ 0
C. Machado
Independent Director1.9yrsUS$226.31k0.0055%
$ 152.0k
Alan Colowick
Independent Director4.3yrsno data0.014%
$ 396.3k
Zhengbin Yao
Independent Director4.9yrsUS$212.67k0.018%
$ 506.6k
4.0yrs
Average Tenure
60.5yo
Average Age

Experienced Board: ALMS's board of directors are considered experienced (4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/20 06:42
End of Day Share Price 2026/05/20 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alumis Inc. is covered by 11 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Eric SchmidtCantor Fitzgerald & Co.
Janani SundararajanChardan Capital Markets, LLC